The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
This study evaluates metabolic and functional parameters in the skeletal muscle of Parkinson's disease patients for comparison to a set of healthy age-matched controls.
Condition or disease
Parkinson Disease, Mitochondrial
The goal of this study is to identify the unique signature of bioenergetic markers and mitochondrial (dys)function in muscle of individuals with PD, who are 65-85 of age, read and speak English, have a Hoehn & Yahr score between 2 and 3 (bilateral disease, not severely disabled) and have a clinical diagnosis of PD. Bioenergetic markers and muscle functional properties will be compared to a control dataset collected over the last few years from healthy elderly subjects in the same age range to provide a foundation for future intervention studies.
Maximal mitochondrial ATP production rates measured by magnetic resonance spectroscopy
NAD(H) metabolites [ Time Frame: baseline ]
Measurement of relative NAD(H) metabolite concentrations in resting skeletal muscle by magnetic resonance spectroscopy
Muscle force and endurance [ Time Frame: baseline ]
Maximum voluntary contraction (MVC) force in Newtons and fatigue resistance assessed by the ability to maintain repeated contractions at 70% MVC will be measured in the hand (flexor digitorum interroseus) and leg (tibialis anterior) using isometric contractions in a custom made apparatus.
Secondary Outcome Measures :
Mitochondrial metabolites [ Time Frame: baseline ]
Separate measurement of NAD(H) metabolite concentrations in cytosol and mitochondria by magnetic resonance spectroscopy in resting skeletal muscle
Relationship between self report function and mitochondrial energetics [ Time Frame: baseline ]
Correlation between self report of fatigue, balance, and muscle pain (PRO-PD) with ATPmax rates and NAD(H) metabolite concentrations measured using magnetic resonance spectroscopy.
Relationship between clinical assessment and mitochondrial energetics [ Time Frame: baseline ]
Correlation between UPDRS with ATPmax and NAD(H) metabolites
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
65 Years to 85 Years (Older Adult)
Sexes Eligible for Study:
Patients diagnosed with Parkinson's disease
Age 65-85 years.
Ability to attend a 3-hour study visit in Seattle, WA.
Ability to read and speak English.
Hoehn & Yahr Stage 2-3. (bilateral disease, not severely disabled.)
Any contra-indication to magnetic resonance imaging
A history of epilepsy, stroke, brain surgery, or structural brain disease.
The presence of other serious illnesses
Current or recent enrollment in a clinical trial involving an investigational product or device.
Supplementation with NAD, nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and other nutraceuticals designed to target NAD for 30 days prior to baseline study visit.
Current drug or alcohol use or dependence.
Inability/unwillingness to provide informed consent. (e.g. diagnosis of dementia, confusion about study goals or participation.)
Acute infection (e.g. upper respiratory, dermal) in the previous 30 days.
Right limb tremor or dyskinesia that cannot be comfortably controlled for 90 minutes.